The Vision of Garden

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Garden has always had a strong focus on patients. Your earnings calls, you'll start with stories about individual patients since health has been impacted by the garden portfolio of products. So going back again to those early days, what was the vision for garden? "We were seeing actually potential for a blood test to shield patients against this cancer"

This week, we’re super excited to have AmirAli Talasaz, co-CEO and co-founder of Guardant Health, a leading precision oncology company focused on helping conquer cancer globally.

Founded in 2011, Guardant Health is focused on helping conquer cancer through the use of its proprietary blood-based tests, vast data sets and advanced analytics. Guardant’s solutions include treatment selection, recurrence detection and early detection of cancer. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Through multiple rounds of private financing, Guardant Health raised over $500 million from investors including Sequoia, Khosla, Lightspeed, OrbiMed, and Softbank, and Pear! and Guardant completed a successful IPO in October 2018.